Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Low Dose MSH2-/- tumor cell vaccine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
pMMR/MSS Advanced Colorectal Cancer
1 trial -
M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors
The George Institute
Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.
1 trial -
M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
Merck Sharp and Dohme
Advanced solid tumors and colorectal cancer
1 trial -
MRx0518
4D Molecular Therapeutics
Pancreatic Cancer
1 trial -
MT-601 dose 200 million cells
Marker Therapeutics
Pancreas Cancer
1 trial -
MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789
AstraZeneca AB
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
Mammaglobin-A DNA Vaccine
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Methylene Blue (50 mg/10ml)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Cancer
1 trial -
Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer Australia Pty Ltd
Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC), Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
Mifepristone and Eribulin in combination
CORCEPT THERAPEUTICS INC
Breast Cancer
1 trial -
Minnelideβ’Capsules
BRIGHT MINDS BIOSCIENCES INC.
Advanced Cancer
1 trial -
Mobocertinib
Takeda
Non-Small Cell Lung Cancer
1 trial -
Molecular imaging with FAPI for diagnosing the CSM4 colorectal cancer subtype
Disc Medicine
Colorectal cancer, liver metastases
1 trial -
NKTR-102
Nektar Therapeutics UK Limited
Advanced Cancer
1 trial -
NKTR-214
Nektar Therapeutics UK Limited
Advanced Cancer
1 trial -
NKTR-214 (Cohort A)
INOVIO PHARMACEUTICALS, INC.
Metastatic Castration-resistant Prostate Cancer
1 trial -
NM1F Injection
TG THERAPEUTICS, INC.
Ovarian Cancer
1 trial -
NP-G2-044
BRIGHT MINDS BIOSCIENCES INC.
Breast Cancer
1 trial -
NX-1607
Nurix Therapeutics
Ovarian Cancer, Epithelial
1 trial -
NXP800 in subjects with Ovarian Cancer
Lacuna Pharma Pty Ltd
Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma
1 trial -
Neratinib Pill
PUMA BIOTECHNOLOGY, INC.
Gastric Cancer
1 trial -
Nimotuzumab and chemotherapy
Biotech Pharmaceutical Co.,
Non-small Cell Lung Cancer
1 trial -
Nivolumab
Jazz Pharmaceuticals Ireland Limited
Small-cell Lung Cancer
1 trial -
Nivolumab
Iovance Biotherapeutics B.V.
Non-Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources